|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on June 28, 2002; DOI 10.1182/blood-2002-02-0471.
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From Bristol-Myers Squibb, Wilmington, DE, and Quest
Diagnostics, San Juan Capistrano, CA.
Thrombocytopenia is a relatively common side effect observed during
glycoprotein (GP) IIb/IIIa antagonist therapy. With the oral
antagonist roxifiban, we observed thrombocytopenia, defined as 50%
reduction of platelets over predose values or below 90 000/µL
(9 × 1010/L), with a frequency of 2% (8 of
386). Thrombocytopenia occurred either early (days 2 to 4) or
delayed (days 11 to 16). No additional cases were observed with up to 6 months of treatment. Retrospective analysis provided evidence for
drug-dependent antibodies (DDABs) to GP IIb/IIIa in 5 of 6 subjects, suggestive of an immune etiology of thrombocytopenia. The
hypothesis that excluding patients based on positive DDAB reaction
would reduce the frequency of thrombocytopenia was tested. Patients
were screened for DDABs during the study qualification period and,
overall, 3.9% of the patients were excluded based on pre-existing DDAB
concentrations above a statistically defined medical decision limit. An
additional 2.6% were excluded based on therapy-related antibody
production during the first 2 weeks. With antibody testing, 0.2% of
patients (2 of 1044) developed immune-mediated thrombocytopenia. One
case developed a rapidly increasing antibody concentration and
presented with thrombocytopenia despite discontinuation of roxifiban
therapy. The second case was related to a false-negative test result.
The frequency of thrombocytopenia was statistically significantly
reduced from 2% to 0.2% (P = .0007) comparing
nonscreened and screened patients. Testing for DDABs can reduce the
frequency of thrombocytopenia in patients treated with roxifiban and,
by analogy, other GP IIb/IIIa antagonists. Thus, DDAB testing may be
employed to increase the safety of GP IIb/IIIa antagonists.
(Blood. 2003;101:58-63) Thrombocytopenia has been observed with all
currently approved glycoprotein (GP) IIb/IIIa antagonists (intravenous
formulations) and a number of developmental candidates.
Thrombocytopenic patients experience more bleeding and ischemic
events.1,2 In the case of approved intravenous agents,
this side effect has been observed with a frequency of up to
5.6%.1-9 In addition, a number of oral GP IIb/IIIa
antagonists have undergone clinical testing, and treatment, for
example, with RPR 109891 was associated with a thrombocytopenia frequency of up to 13%.10 Lower frequencies have been
observed for the other oral agents in clinical development. For
sibrafiban, the thrombocytopenia frequency was not different compared
with placebo,11 whereas in the case of orbofiban,
increased frequencies were observed in the treatment
arms.12 We recently reported 2 patients with drug-induced
thrombocytopenia associated with roxifiban treatment.13
The sample size was too small to obtain accurate estimates as to the
frequency of thrombocytopenia or to generalize as to the prevailing
pathomechanism in the patient population treated with roxifiban.
Some general risk factors for thrombocytopenia induced by GP IIb/IIIa
antagonist therapy have been identified, including advanced age, lower
body weight, and lower baseline platelet count.1,2 Retrospective studies in humans and preclinical animal models implicated drug-dependent antibodies (DDABs) to GP
IIb/IIIa in the etiology of thrombocytopenia. For example, a
chimpanzee presented with acute thrombocytopenia upon treatment with GP
IIb/IIIa antagonists.14 Platelet fluorescence-activated
cell sorter (FACS) analysis provided evidence for the presence
of GP IIb/IIIa antagonist-dependent antiplatelet antibodies to GP
IIb/IIIa antagonist that elicited thrombocytopenia but not to
antagonists that were well tolerated in the same
chimpanzee.14 Support for the immune nature of
thrombocytopenia in humans is derived from 2 patients treated with
roxifiban, an orally bioavailable GP IIb/IIIa antagonist. Both patients
underwent conversion to a highly positive drug-dependent antibody
status temporally associated with thrombocytopenia.13
Previous studies are consistent with the hypothesis that the antibodies
bind to platelets in a roxifiban-dependent manner via their ability to recognize roxifiban-induced conformational changes in GP
IIb/IIIa.13
Here, we report that thrombocytopenia is a relatively common side
effect during treatment with roxifiban and occurs with a frequency of
about 2%. Thrombocytopenia was observed either early (days 2 to 4)
or delayed (days 11 to 16). No additional cases occurred beyond
this susceptible time period. Most cases presented with drug-dependent
antibodies to GP IIb/IIIa. Thus, we tested the hypothesis that
prospective testing for pre-existing or increasing DDAB concentrations
would reduce the incidence of thrombocytopenia in patients treated with
roxifiban. Patients were tested for the presence of pre-existing DDABs
prior to enrollment and during the first 2 weeks of therapy. We provide
evidence that controlling patient enrollment based on DDAB status
significantly reduces the incidence of GP IIb/IIIa antagonist-induced
thrombocytopenia, further supporting the immune etiology of GP IIb/IIIa
antagonist-induced thrombocytopenia.
Study populations
Quantification of free DDABs in plasma
Quantification of platelet-bound and free DDABs DDABs to roxifiban bind to conformationally sensitive epitopes in GP IIb/IIIa.13 EDTA (ethylenediaminetetraacetic acid) treatment of platelets at 37°C results in the dissociation of the GP IIb/IIIa complex on intact platelets,15-18 leading to the release of bound antibodies that recognize complex-specific determinants induced by roxifiban.13 After removal of platelets by centrifugation, the resulting plasma is expected to contain free and previously platelet-bound conformationally sensitive DDABs. To test whether quantification of the platelet-bound and free pool of DDABs increases the sensitivity of the DDAB ELISA, blood from patients enrolled in DMP 754-017 was collected into vacutainers containing 15% EDTA, heat-treated at 37°C for 1 hour with end-over-end rocking, and PPP prepared as above. A parallel sample was also collected in sodium citrate and archived.EDTA treatment also dissociates roxifiban from the platelet surface, precluding the direct analysis of the plasma by the differential ELISA (antibody binding in the presence and absence of roxifiban). A roxifiban removal step with C18 (Orochem), a hydrophobic matrix with high affinity for roxifiban, was included. Briefly, 50 mg of the hydrophobic matrix was activated with 100% methanol and then equilibrated with buffer. EDTA PPP (500 µL containing 100 nM DuP 714 [final concentration], an in-house thrombin inhibitor, and 0.32% sodium citrate) was incubated with the matrix for 15 minutes. PPP was recovered by centrifugation at 2500g for 5 minutes. Control experiments (not shown) revealed that the drug absorption procedure reduced the roxifiban concentrations to a level not interfering with the differential ELISA. In addition, DDABs are not absorbed from plasma specimens. The following changes were included compared with the "quantification of free DDABs in plasma" method, including use of less diluted plasma (1/10), and procedures aimed at reducing the background. The latter consisted of IgG depletion of purified GP IIb/IIIa13 and GP IIb/IIIa antagonist addition in the "no-drug" control wells during the detection step with the secondary antibody. The latter procedure reduced the background readings of some plasmas, thereby increasing the signal-to-noise ratio of the assay. Although the mechanism of background reduction by roxifiban has not been completely elucidated, it may be related to the dissociation of conformationally sensitive, non-drug-dependent antibodies from the ELISA plate. Result reporting and quality assurance The prospective use of the assay required rapid turnaround of results (24 to 48 hours) for specimens shipped on dry ice from the various clinical sites. Analysis was performed under good laboratory practice (GLP) guidelines at Covance (Vienna, VA). The assay format incorporated both positive and negative controls on all plates. Plate acceptance and rejection criteria were established initially using citrate plasma from a previously described DDAB-positive thrombocytopenic patient (patient 330 described by Billheimer et al13). Briefly, this patient experienced a thrombocytopenic episode in a previous trial with roxifiban. This quality control material was replaced during the first clinical study with a renewable source of antibodies (a recombinant chimeric DDAB [rJK094]). Briefly, the antibody was derived using standard hybridoma technology after immunization of mice with purified GP IIb/IIIa/roxifiban complexes. Resulting hybridomas were screened in the differential ELISA, and one clone with differential reactivity was isolated, cloned, and the constant region replaced with human IgG4 (K. O'Neil et al, unpublished data, 2002). This antibody was used as a positive control after cross-validation with plasma from patient 330. Changes in absorbance after substrate addition were determined kinetically for 5 minutes at 650 nm or until the change in absorbance reached 0.5 optical density (OD) units. The kinetic reading is insensitive to minor variations in the time of substrate addition to individual wells. In addition, specimens with different background readings (signal in the absence of roxifiban addition) can be accommodated on the same ELISA plate.13 Results are expressed as delta ([Vmax + compound] [Vmax compound]). Assays were
performed with triplicate determinations, and a coefficient of
variation around the cutoff of less than 15% was observed.
Limited stability studies revealed that the DDAB concentration was
unchanged in samples stored for up to 2 years. The ELISA results from
108 nonthrombocytopenic subjects treated with roxifiban (predose
samples from a previous phase 2 roxifiban study13) were
used to derive a statistical cutoff value (medical decision level) with
a positive rate of 5% (delta = 12 for "quantification of
free DDABs" and a 1/20 sample dilution, and delta = 35 for
"quantification of platelet-bound and free DDABs" and 1/10 sample
dilution; 95th percentile of nonparametric rank order test).
Miscellaneous Platelet absorption studies were performed as described previously.13 For all in vitro studies, XP280, the salt of the active, free acid form of the prodrug roxifiban was employed.19
Frequency of thrombocytopenia in patients treated with roxifiban in the absence of DDAB testing A total of 386 patients with CAD or peripheral artery disease (PAD) were treated with roxifiban without DDAB testing (retrospective testing in Table 1). Eight cases of thrombocytopenia were observed (Table 1). The frequency of thrombocytopenia was not different between CAD (4 of 203) and PAD (4 of 175) clinical trials (Table 1). The statistical power of the clinical studies was insufficient to determine whether thrombocytopenic patients differed by age, sex, weight, or morbidity and mortality. The overall frequency of thrombocytopenia in the patient group was 2.1%. Half of the cases occurred early (days 2 to 4), whereas the other half presented with delayed (days 11 to 16) thrombocytopenia. The vulnerable period for thrombocytopenia appears to be the first 3 weeks of treatment. Additional cases were not observed in patients treated for up to 6 months. The extent of thrombocytopenia varied from moderate to severe (platelets < 20 000/µL [2 × 1010/L]). In all cases, treatment with roxifiban was discontinued, and patient safety was ensured by close clinical and laboratory monitoring and by hospitalization and platelet infusions if required. None of the thrombocytopenic patients experienced major bleeding episodes at the time of thrombocytopenia, and all patients recovered without additional sequelae. Based on the availability of specimens, retrospective testing for DDABs was performed as indicated. Five of 6 patients tested positive for DDABs. Some patients were already antibody positive prior to treatment, whereas others developed an increase in antibody titer temporally associated with the thrombocytopenic events. These observations suggest that the prevailing pathomechanism for thrombocytopenia in this patient population is immune-mediated platelet clearance and/or destruction.
Implementation of testing for free DDABs in a phase 2 study with a drug holiday With the observation that thrombocytopenia is a relatively common side effect of roxifiban, we tested the hypothesis that prospective testing for DDAB reduces the frequency of thrombocytopenia. Patients negative by ELISA entered into a qualification period and were treated with roxifiban on 5 consecutive days, followed by a drug holiday for 9 days. Additional antibody testing was performed on days 7 and 14. A confirmed positive DDAB result was used as an exclusion criterion. The remaining patients entered into a 6-month treatment phase. Platelet counts were taken to further ensure patient safety. A total of 4.3% of patients (57 of 1332) tested positive at prescreen, 0.5% (4 of 823) tested positive for DDAB at day 7-8, and an additional 2.2% (18 or 821) tested positive on day 14. Note that some of the subjects were not enrolled because other study enrollment criteria were not met. During this study, one patient (99016) tested negative for the presence of DDABs at prescreen and developed thrombocytopenia on day 14, 9 days after discontinuation of drug treatment. The temporal association between increase in antibody concentration and reduction in platelet count is illustrated in Figure 1A. A strong positive DDAB response was detected in the day 14 plasma (Figure 1A). Notably, platelet GP IIb/IIIa serves as a reservoir for roxifiban, and blood concentrations are estimated to be 1 to 2 nM 9 days after discontinuation of treatment. This drug level is sufficient for a maximal response in the DDAB ELISA13 and predicts an occupancy of 5% of GP IIb/IIIa binding sites in vivo. Thus, these data do not argue against DDABs being causative for thrombocytopenia during a drug holiday. The relationship between the antibody present in plasma and the pathogenetic antibody is suggested by the following observations. Platelet absorption studies revealed that the ELISA-positive DDAB bound to gel-purified platelets in the presence but not absence of roxifiban. Moreover, antibodies could be dissociated from the platelet surface by EDTA treatment, a condition previously reported to disrupt the GP IIb/IIIa complex (not shown).
Reanalysis of the predose sample of patient 99016 provided evidence for an inconsistently detectable antibody concentration (3 of 7 determinations were positive). Additional studies suggested a low-affinity DDAB with binding being sensitive to the washing conditions of the ELISA plate. Replacing the automated plate washer with a "hand wash" enabled consistent detection of this antibody (Figure 1B). Comparison of serial dilutions of the prescreen versus day 19 specimen provided evidence for a 20-fold increase in antibody concentration (Figure 1B). Additional plasma samples were obtained from 7 patients who were negative upon prescreen but were excluded from the clinical trial based on a positive antibody concentration (Figure 1C). No significant change in platelet counts was observed in these patients. Implementation of testing for free and platelet-bound DDABs in a phase 2 study without drug holiday With the aim of capturing free and platelet-bound DDABs to roxifiban in plasma and thereby decreasing the time required to detect a serum conversion in patients not presenting with pre-existing antibodies, a modified DDAB ELISA was implemented in a second phase 2 study. The key change is EDTA treatment of platelets to release platelet-bound DDABs that recognize complex-specific GP IIb/IIIa epitopes (see "Patients, materials, and methods"). Patients with negative prescreen were continuously treated up to 180 days, and additional DDAB testing was performed on days 7, 10, and 14. A total of 5.4% of patients were excluded from the study: 3.0% of patients (15 of 493) were excluded from the study based on a prescreen, and an additional 2.4% (8 of 342) tested positive during either days 7-8, day 10, or day 14-15. Some of the prescreened subjects were not enrolled because other study criteria were not met. We observed one case of thrombocytopenia (Figure 2A). The patient (21013) tested negative for the presence of DDABs prior to drug treatment and received roxifiban for 8 days. DDAB analysis of the day 8 sample was positive (delta = 90). The physician was notified, the patient hospitalized, and drug treatment terminated. A further rapid increase in DDAB concentration was observed, coinciding with a sharp fall in platelet number (Figure 2A). Reanalysis of the predose and day 3 and 5 specimen by both the EDTA ( ) and citrate ( ) methodologies
failed to detect antibodies at earlier time points (Figure 2A). Thus,
thrombocytopenia was either elicited by a de novo immune response or
the sensitivity of the ELISA was insufficient to detect pre-existing
antibodies in this patient.
Treatment with roxifiban was discontinued in 7 additional patients due to a developing DDAB concentration without a significant reduction in platelet count. The time course of serum conversion of 3 representative patients is depicted in Figure 2B-D. To test whether the EDTA elution facilitated earlier detection of serum conversion, specimens were retrospectively analyzed by both methods (Figure 2). Overall, the time courses of serum conversion were very similar between the EDTA and citrate samples, suggesting that the EDTA procedure had little benefit in detecting a rise in antibody concentration at earlier time points due to elution of platelet-bound IgG. Studies were performed to delineate whether ELISA-detectable antibodies
have the propensity to be pathogenetic (platelet-binding antibodies)
or, alternatively, recognize epitopes elicited in GP IIb/IIIa by the
immobilization procedure used in the assay procedure. DDAB-containing
plasma was incubated with platelets in the presence or absence of
roxifiban and reanalyzed in the DDAB ELISA. The results are summarized
in Table 2. Platelet absorption reduced
the ELISA-detectable antibody concentration in the presence but not
absence of roxifiban, indicating the specificity of the platelet
absorption. These results indicate that the antibodies have the
propensity to bind to intact platelets in a drug-dependent manner.
These observations are consistent with the possibility that
discontinuation of roxifiban treatment based on the positive DDAB test
may have prevented thrombocytopenia.
Effects of prospective testing for DDABs on the frequency of thrombocytopenia Thrombocytopenia frequencies were compared between clinical trials as a function of the use of the DDAB ELISA to control patient enrollment. All patients included in the comparison presented with advanced atherosclerotic vascular disease. Although different DDAB testing protocols were employed (free DDABs versus free and platelet-bound DDABs), the test results were similar for both test methods (compare free versus free and platelet DDAB time courses in Figure 2). The treatment intervals with respect to the drug holiday were different between the studies. However, the thrombocytopenia observed during the drug holiday (Figure 1), 9 days after discontinuation of treatment, appears to be the result of drug exposure. These considerations suggest that a drug holiday was not fully operative. A 2.1% frequency of thrombocytopenia was observed when 386 patients were enrolled without negative DDAB result as an inclusion criterion. Of the 1044 patients treated after DDAB testing, 2 patients developed thrombocytopenia, with an overall frequency of 0.2%. Statistical analysis revealed a highly significant (P = .0007) reduction of thrombocytopenia when a negative DDAB test was used as an inclusion criterion (Table 3), further supporting the immune nature of thrombocytopenia during treatment with roxifiban. In a subgroup analysis, the statistical evaluation was limited to CAD patients. Despite reduced sample size, the reduction in thrombocytopenia frequency by DDAB testing was still highly significant (P = .0078). Taken together, these observations suggest that thrombocytopenia during treatment with roxifiban can be prevented by testing for DDABs.
Thrombocytopenia during treatment with roxifiban occurred during 2 time periods, either early in the first 4 days of treatment (early-onset thrombocytopenia) or within 11 to 16 days (delayed-onset thrombocytopenia). No additional cases were observed with up to 6 months of roxifiban treatment. Thus, the critical time frame for the development of thrombocytopenia during treatment with roxifiban is the first 3 weeks. The implication of these findings is that patient safety should be ensured by closely monitoring the platelet counts during this time period or, potentially, using DDAB testing. However, the clinical utility of DDAB testing needs confirmation in large clinical trials. The results presented here further support the immune nature of thrombocytopenia during treatment with the GP IIb/IIIa antagonist roxifiban. This conclusion is based on the observation that controlling patient enrollment using a positive DDAB ELISA test result prior to or during treatment as an exclusion criterion statistically significantly reduced the incidence of thrombocytopenia. In addition, with the exception of one patient, DDABs could be demonstrated by retrospective analysis in all patients with thrombocytopenia when specimens were available. It remains unclear whether this patient experienced a nonimmune-mediated thrombocytopenia or the assay failed to detect this specific antibody. Overall, the frequency of nonimmune-mediated thrombocytopenia during roxifiban treatment must be very low. The medical decision level employed in these studies was based on a statistically based cutoff level for DDAB concentration derived from nonthrombocytopenic patients of a previous phase 2 trial of roxifiban. The clinical studies were not designed to determine the false-positive rate of the DDAB ELISA, because patients with positive antibody reaction were excluded from the study. However, some estimates as to the false-positive rate can be obtained by comparing clinical trials with and without the prospective use of the DDAB ELISA. For example, between 5% (free and platelet-bound DDABs) and 7% (free plasma DDAB) of patients were excluded from the study based on a positive antibody reaction at prescreen or during treatment. Assuming a thrombocytopenia frequency of 2%, the false-positive rate could be as high as 5%. This false-positive rate would be, in our view, unacceptable for routine clinical use. However, it should be noted that further clinical studies may help to optimize the clinical decision level to reduce the false-positive rate. In addition, patients presenting with a positive DDAB test prior to treatment may benefit from more extensive monitoring. The observed false-negative rate is low (0.1%). The false-negative test result (1 subject) was not due to a nonimmune nature of the thrombocytopenia. Further characterization of this plasma provided evidence for low-affinity antibodies and, after assay modifications to efficiently capture these antibodies, the prescreen was positive. Because of the potential serious sequelae of thrombocytopenia, false positives are preferable over false negatives. A number of patients developed a positive antibody reaction during treatment with roxifiban, and drug treatment was stopped. Analysis of these time-course plasmas from study by platelet depletion (Table 2) revealed that most of the antibodies bound to platelets. This observation suggests that the patients were at increased risk for thrombocytopenia. Two factors may explain why thrombocytopenia was not observed in these patients. First, DDABs derived during treatment with roxifiban are exquisitely drug dependent,13 and discontinuation of treatment may have reduced the roxifiban blood concentration below levels required for sufficient antibody binding to platelets. Second, none of these plasmas presented with antibody concentrations as high as those observed in thrombocytopenic patients (compare Figure 2 and data by Billheimer et al13). Whole blood was collected from patients presenting with an increase in antibody concentration in either sodium citrate or EDTA to test whether EDTA dissociation of platelet-bound DDABs that are complex specific alters the time to serum conversion. Generally, we observed an increased DDAB concentration in samples collected in EDTA compared with citrate. However, the increase was modest, and little effect on time to reach the medical decision level was observed. These observations suggest that platelet elution has little advantage and does not justify the additional preassay sample-processing procedures required. This finding is consistent with the idea that antibody-loaded platelets are cleared by the reticuloendothelial system rather than retained in the circulation. All cases of thrombocytopenia observed with roxifiban fall into 2 categories. Early-onset thrombocytopenia occurs within the first 4 days of treatment. We observed 4 cases in the absence of DDAB testing, whereas none was observed in the presence of prospective DDAB testing. The available data are consistent with the notion that early-onset thrombocytopenia is immune mediated and that the incidence can be reduced by screening patients for DDAB prior to therapy. Delayed-onset thrombocytopenia occurs within the second or third week of treatment. Of the 6 cases in our roxifiban trials, 3 presented with a pre-existing antibody concentration, whereas 3 developed detectable antibodies during treatment. These observations suggest that a second DDAB test during treatment would be required to maximize the utility of the DDAB testing. We also observed that the time interval between DDAB concentration rise and clinically significant reduction in platelet count varied between patients. Many factors, including "bone marrow reserve," and DDAB concentration, affinity, and binding sites on GP IIb/IIIa are expected to affect the propensity to develop thrombocytopenia. In one instance, the rise in antibody concentration was closely followed by thrombocytopenia and could not be prevented by discontinuation of drug treatment. In this case, the DDAB testing was positive prior to a significant fall in platelet counts and allowed for improved patient management in a hospital setting. All cases of delayed-onset thrombocytopenia could be detected by a second test on day 8 after initiating drug therapy. Thus, a prescreen and a day 8 test appear sufficient to significantly reduce the incidence of thrombocytopenia. It remains to be established whether the clinical experience and conclusions related to patient management presented here can be extended to other chemical classes of GP IIb/IIIa antagonists.
Submitted February 13, 2002; accepted June 13, 2002.
Prepublished online as Blood First Edition Paper, June 28, 2002; DOI 10.1182/blood-2002-02-0471.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Dietmar Seiffert, Department of Chemical Enzymology, Bristol-Myers Squibb, Experimental Station, E400/3255, PO Box 80400, Wilmington, DE 19880-0400; e-mail: dietmar.seiffert{at}bms.com.
1.
Berkowitz SD, Sane DC, Sigmon KN, et al.
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization.
J Am Coll Cardiol.
1998;32:311-319
2.
McClure MW, Berkowitz SD, Sparapani R, et al.
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome.
Circulation.
1999;99:2892-2900 3. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435[CrossRef][Medline] [Order article via Infotrieve].
4.
Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization: the EPILOG Investigators.
N Engl J Med.
1997;336:1689-1696 5. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: the EPISTENT Investigators: evaluation of platelet IIb/IIIa inhibitor for stenting. Lancet. 1998;352:87-92[Medline] [Order article via Infotrieve].
6.
Berkowitz SD, Harrington RA, Rund MM, Tcheng JE.
Acute profound thrombocytopenia after c7E3 (abciximab) administration.
Circulation.
1997;95:809-813 7. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol. 1996;78:1161-1166[Medline] [Order article via Infotrieve].
8.
Tcheng JE, Kereiakes DJ, Lincoff AM, et al.
Abciximab readministration: results of the ReoPro Readministration Registry.
Circulation.
2001;104:870-875 9. Hongo RH, Brent BN. Association of eptifibatide and acute profound thrombocytopenia. Am J Cardiol. 2001;88:428-431[CrossRef][Medline] [Order article via Infotrieve]. 10. Giugliano RP, McCabe CH, Sequeira RF, et al. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitory (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J. 2000;140:81-93[CrossRef][Medline] [Order article via Infotrieve]. 11. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial: the SYMPHONY Investigators: sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Lancet. 2000;355:337-345[CrossRef][Medline] [Order article via Infotrieve].
12.
Cannon CP, McCabe CH, Wilcox RG, et al.
Oral glycoprotein IIb/IIIa inhibition by orbofiban in patients with unstable coronary syndromes (OPUS-TIMI16) trial.
Circulation.
2000;102:149-156
13.
Billheimer JT, Dicker IB, Wynn R, et al.
Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated.
Blood.
2002;99:3540-3546
14.
Bednar B, Cook JJ, Holahan MA, et al.
Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa.
Blood.
1999;94:587-599
15.
Shattil SJ, Brass LF, Bennett JS, Pandhi P.
Biochemical and functional consequences of dissociation of the platelet membrane glycoprotein IIb-IIIa complex.
Blood.
1985;66:92-98 16. Ginsberg MH, Loftus JC, Plow EF. Cytoadhesins, integrins, and platelets. Thromb Haemost. 1988;59:1-6[Medline] [Order article via Infotrieve]. 17. Kieffer N, Phillips DR. Platelet membrane glycoproteins: functions in cellular interaction. Annu Rev Cell Biol. 1990;6:329-357[CrossRef]. 18. Khaspekova SG, Vlasik TN, Byzova TV, Vinogradov DV, Berndt MC, Mazurov AV. Detection of an epitope specific for the dissociated form of glycoprotein IIIa of platelet membrane glycoprotein IIb-IIIa complex and its expression on the surface of adherent platelets. Br J Haematol. 1993;85:332-340[Medline] [Order article via Infotrieve]. 19. Olson RE, Sielecki TM, Wityak J, et al. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action. J Med Chem. 1999;42:1178-1192[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  R. H. Aster Immune Thrombocytopenia Caused by Glycoprotein IIb/IIIa Inhibitors Chest, February 1, 2005; 127(2_suppl): 53S - 59S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schwarz, Y. Katagiri, M. Kotani, N. Bassler, C. Loeffler, C. Bode, and K. Peter Reversibility versus Persistence of GPIIb/IIIa Blocker-Induced Conformational Change of GPIIb/IIIa ({alpha}IIb{beta}3, CD41/CD61) J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1002 - 1011. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) is
indicated. (B) Prescreen citrated plasma samples of patient 99016, as
well as peak DDAB samples, were reanalyzed by the DDAB ELISA. The
washing steps with an automated plate washer were replaced by gentle
"hand washing" using a multichannel pipettor. Note that
the prescreen of patient 99016 is clearly positive using these assay
modifications. (C) An increase in antibody concentration was observed
in 5 additional patients (identified by ID numbers). Patients
were excluded from the study based on a confirmed positive test result
and participated in follow-up antibody testing. The antibody
development (Delta ELISA) as a function of time is indicated (day 1 equals start of qualification period). The platelet counts did not
change significantly from baseline values.
. (A) Patient 21013 developed severe thrombocytopenia
on day 11. Drug treatment was stopped on day 9 based on a rapidly
increasing antibody concentration. The patient was hospitalized for
monitoring. (B) Patient 49007 was excluded from the study on day
11. (C) Patient 61003 was excluded from the study on day 11. (D) Patient 7013 was excluded from the study on day 11.